SynthesisCell biochemistry and biophysics2025
The Pharmacological Spectrum of Hispidulin: A Thorough Systematic Review and Meta-analysis.
Synthesis in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plant-Derived Secondary Metabolites Modulating Inflammation-Driven Pathways in Hepatocellular Carcinoma: Preclinical Insights.Current issues in molecular biology · 2026Review
- In silico screening and molecular analyses identify apigenin from Scutellaria barbata as a potent AKT1 inhibitor in breast cancer.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phytochemicals have historically played a crucial role in promoting health and well-being. Hispidulin, a plant-derived metabolite, has exhibited several pharmacological applications. Despite existing research on hispidulin, a comprehensive understanding of its mechanistic pathways remains limited. Our objective is to investigate the pharmacological and biochemical cellular effects of this compound through dose analysis in a meta-analysis. Our analysis of 39 studies was conducted in accordance with the PRISMA guidelines. Key biomarkers associated with hispidulin’s pharmacological response include TNF-α, iNOS, Nrf2, HO-1, Bax, and Caspase-3. A subgroup analysis indicated that hispidulin enhanced antioxidant defense mechanisms via the Nrf2 and HO-1 pathways, while reducing pro-inflammatory markers, including TNF-α, IL-1β, and iNOS, at significantly lower doses. Additionally, dose-dependent increases in caspase-3 and Bax expression, along with a reduction in Bcl-2 levels, enhanced cell death. These dose-dependent modulations may benefit therapeutic trials and clinical translation. Our data corroborate hispidulin’s therapeutic potential and its capacity to suppress tumor growth and inflammation more effectively than oxidative effects. The findings suggest that hispidulin possesses therapeutic potential, as it reduced tumor development and inflammation more effectively than oxidative effects.
Indexed as
Identifiers
40839205What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.